|This article relies too much on references to primary sources. (September 2012) (Learn how and when to remove this template message)|
|Public (NYSE: BIO)|
|Founders||David and Alice Schwartz|
|Headquarters||Hercules, California, U.S.A.|
Christine Tsingos (Executive Vice President, CFO)
Michael Crowley (Executive Vice President, Global Commercial Operations)
Shannon Hall (Executive Vice President, President Life Sciences Group)
John Hertia (Executive Vice President, President Clinical Diagnostics Group)
Ronald Hutton (Vice President, Treasurer)
James Stark (Vice President, Corporate Controller)
|Revenue||US$2.1 billion (FY 2013)|
|US$295 million (FY 2011)|
|US$178 million (FY 2011)|
|Total assets||US$3.711 billion (FY 2015)|
|Total equity||US$1.744 billion (FY 2010)|
Number of employees
Bio-Rad Laboratories, Inc. was founded in 1952 in Berkeley, California. The company was initially engaged in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. Today, Bio-Rad manufactures and supplies life science research, healthcare, analytical chemistry, and other markets with products and systems used to separate complex chemical and biological materials and to identify, analyze, and purify their components.
Bio-Rad operates in two industry segments: Life Science and Clinical Diagnostics. Both segments operate worldwide. Bio-Rad's customers include hospitals, major research institutions, public health, commercial laboratories, Biotechnology and Pharmaceutical Companies,and Food Safety. Bio-Rad's headquarters are in Hercules, California. The company has offices and facilities worldwide and more than 7,750 employees. Bio-Rad had revenues of more than two billion dollars in 2011. The company has been listed on the New York Stock Exchange since October 24, 2008. Before that, Bio-Rad was listed on the American Stock Exchange.
Life Science Research
Life science is the study of the characteristics, behavior, and structure of living organisms and their component systems. Life science researchers use a variety of products and systems — including reagents, instruments, software, and apparatus — to advance drug discovery, biotechnology, food pathogen testing, and the study of life processes, primarily within a laboratory setting. Bio-Rad’s products are based on technologies used to separate, purify, identify, analyze, and amplify biological and chemical materials.
Bio-Rad ranks among the top five life science companies in the world and maintains a solid reputation for quality and innovation. The Life Science Group provides a wide range of laboratory instruments, apparatus, and consumables used for research in functional genomics, proteomics, and food safety. The company holds leadership positions in eletrophoresis, protein assays, BSE (or mad cow disease) and CWD (chronic wasting disease) testing, gel image analysis, DNA amplification, and biochromatography. The primary end users in Bio-Rad’s sectors of the market are universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, and food testing laboratories.
Bio-Rad is the number one specialty diagnostics company in the world. The Clinical Diagnostics Group develops, manufactures, sells and supports a large portfolio of products for medical screening and diagnostics. The company holds leadership positions in diabetes monitoring and quality control (QC) systems. Bio-Rad is well known for its blood virus testing and detection, blood typing, autoimmune and genetic disorders testing and Internet-based software products.
Bio-Rad's Clinical Diagnostics segment encompasses a broad array of technologies incorporated into a variety of products used to detect, identify, monitor, and quantify substances in patient and donor blood, other bodily fluids, and tissue samples. The vast majority of these tests are performed in vitro (outside the body). The information generated by these tests helps physicians diagnose disease and guide therapy and treatment to help improve patient care.
The market is split into several subsegments consisting of clinical chemistry, immunoassay, microbiology, hematology, molecular, coagulation, blood banking, and blood typing. Bio-Rad has significant positions in blood virus testing (blood banking and immunoassay); immunohematology (blood typing); hemoglobin A1c testing for diabetes monitoring (clinical chemistry and immunoassay); autoimmune disease testing (immunoassay); and quality control (crossing all subsegments).
Consumers of Bio-Rad’s clinical diagnostic products are hospital laboratories, reference laboratories, physician office laboratories, government agencies, and diagnostic manufacturers.
One medically significant product is a rapid dengue test, called the NS1 antigen test, which allows for dengue detection the first day of fever, rather than when antibodies rise some five or more days later.
Bio-Rad Laboratories was founded in 1952 by husband and wife team David and Alice Schwartz. The couple first met in a class at the University of California–Berkeley, from which they both graduated.
The idea that launched the company came about unexpectedly during a game of bridge. During the card game, the players, including Dave and Alice, joked about products that were not but maybe should have been on the market. Someone suggested creating tobacco mosaic virus, a virus Alice was using for scientific research and one that required many days to prepare. Dave questioned why no one was manufacturing it. The following day, he and Alice searched their neighborhood in Berkeley for a place to launch a company with a mission to accelerate the scientific discovery process by providing products and tools to researchers.
In the years that followed, the couple continued to expand their product line. They worked closely with their customers to gain a better understanding of what researchers were trying to accomplish and how.
In 1967, Bio-Rad entered the field of clinical diagnostics with the development of its first test kit based on separation techniques and materials developed for life science research. Bio-Rad expanded into the field of analytical and measuring instrument systems through internal research and development efforts and acquisitions in the late 1970s and 1980s. In 1999, Bio-Rad acquired the stock of Pasteur Sanofi Diagnostics. This strengthened the company’s position in the HIV and infectious disease diagnostic product market. In 2000 and 2004, Bio-Rad divested its semiconductor, optoelectronic metrology, and confocal microscopy product lines. In late 2007, Bio-Rad acquired Switzerland-based DiaMed Holding AG, enhancing Bio-Rad’s position in the immunohematology market and in January 2013, the Company purchased AbD Serotec, a division of MorphoSys AG. This added Serotec’s more than 15,000 antibodies, kits, and accessories to Bio-Rad’s portfolio of research and clinical diagnostic products.
As Bio-Rad broadened its product line, it also expanded its geographical market. Bio Rad has distribution channels in more than 30 countries outside the United States through subsidiaries whose primary focus is customer service and product distribution. One of their most prominent representatives was David E. Garfin.
bioradiations is an online magazine created by Bio-Rad Laboratories, Inc. that offers scientific professionals around the globe whitepapers, tips, techniques, and topics related to Bio-Rad products and services. bioradiations originated as a print magazine that was launched in 1965 and was in continuous publication until 2011. Content typically includes new product information, technical and application notes describing experiments performed using Bio-Rad products, and interviews with researchers in the life sciences. The online version offers interactive content including product demonstrations in the form of system tours, videos, podcasts etc. Visit bioradiations.
- "Bio-Rad Laboratories, Form 10-K, Annual Report, Filing Date Feb 29, 2012" (PDF). secdatabase.com. Retrieved Feb 14, 2013.
- Bio-Rad Laboratories Form 10-K 2008. | http://ir.10kwizard.com/download.php?format=PDF&ipage=6171459&source=432
- About Bio-Rad | https://www.bio-rad.com/evportal/en/US/evolutionPortal.portal?_nfpb=true&_pageLabel=abtBioRadLanding_page
- Bio-Rad Laboratories Annual Report 2011. | https://www.bio-rad.com/evportal/evolutionPortal.portal?_nfpb=true&_pageLabel=corporateannualreports_page&reportsyear=2011
- Bio-Rad Annual Report 2008 | https://www.bio-rad.com/webroot/web/pdf/corporate/literature/2008_annual.pdf
- "David Schwartz". Chemical Heritage Foundation. Retrieved 4 December 2014.
- "Past Winners of the Pittcon Heritage Award". Chemical Heritage Foundation. Retrieved 4 December 2014.
- "Past Winners of the Richard J. Bolte Sr. Award for Supporting Industries". Chemical Heritage Foundation. Retrieved 4 December 2014.
- Burress, Charles (April 6, 2012). "Bio-Rad Cofounder David Schwartz of El Cerrito: 1923–2012". El Cerrito Patch. Retrieved 4 December 2014.
- Mark, Barry. "Revenue Update on Bio-Rad Laboratories, Inc.". Markets Bureau. Retrieved 4 March 2015.
- "Bio-Rad Acquires AbD Serotec from MorphoSys". Genetic Engineering & Biotechnology News. 17 December 2012.
- The PCR Song. | http://www.youtube.com/watch?v=x5yPkxCLads
- Official website
- Bioradiations - Bio-Rad's trade journal since 1965.
- Bio-Rad Laboratories SEC Filings
- AbD Serotec (now Bio-Rad Antibodies)
- Wall Street Journal profile